Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly metabolized by tissue esterase that it does not accumulate even after infusion for long periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also, hemodynamic stability compared to propofol gives clinicians preference to use for geriatric anesthesia. However, the study on the effect of remimazolam compared to propofol on postoperative delirium have not been carried out. The purpose of the study is to compare the incidence of postoperative delirium and recovery profile in elderly patients undergoing orthopedic surgery using either remimazolam or propofol.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
82
Remimazolam is continuously infused based on bispectral index (within 40-60).
Propofol is continuously infused based on bispectral index (within 40-60).
Sanggye Paik hospital
Seoul, South Korea
RECRUITINGIncidence of delirium 3 days after the end of operation
delirium is evaluated preoperatively and 3 days after surgery using Mini-Mental State Examination
Time frame: Upto 3 days after surgery
quality of recovery (QoR-15) 3 days after the end of the operation
QoR-15 survey is performed preoperatively and 3 days after surgery.
Time frame: Upto 3 days after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.